Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …

Although it is recognized that airway inflammation is key to asthma pathogenesis, the
marked heterogeneity in its clinical course and variations in response to treatment make it a …

In severe refractory asthma, both an understanding of the underlying pathophysiologic
mechanisms driving airway inflammation and the identification of appropriate biomarkers in …

Severe asthma is a complex multifactorial disease that requires specialist multidisciplinary
input for optimal clinical outcomes. Following multidimensional assessment for optimisation …

Asthma is a multifaceted disease and is associated with significant impairment and risk, and
a therapeutic response that is highly variable. Although current treatments are usually …

Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging,
we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce …

Undeniably, childhood asthma is a multifactorial and heterogeneous chronic condition
widespread in children. Its management, especially of the severe form refractory to standard …

During the last decades, new treatments targeting disease mechanisms referred as
biologics have been introduced in the therapy of asthma and currently, five monoclonal …

Introduction: It is estimated that 5–10% of asthma patients suffer from severe asthma. Severe
asthma is associated with increased morbidity and mortality. These patients are not …

Asthma is a chronic inflammatory disease of the airways which can have a detrimental effect
on quality of life and in extreme cases cause death. Although the majority of patients can …